NOT that I remotely suggesting it statistically significant at only 15 patients (or being critical of MSB before the usual recriminations start) but MSB's recent GvHD trial reported:
"Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in recently published studies of children or adults with SR-aGVHD who received best available therapy (BAT) or the only approved agent in adults".
CYP reported "Patients treated with CYP-001 had a two-year overall survival rate of 60% (9/15 patients)" by comparison in its small phase 1 trial.
Ann: Two-Year Results of Phase 1 SR-aGvHD Trial Presented at ISCT, page-2
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.39M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.0¢ | 26.0¢ | $16.45K | 60.18K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12565 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.0¢ | 39586 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
| CYP (ASX) Chart |